Correction

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

N Engl J Med 2003; 349:1100September 11, 2003

Article

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America (Original Article, N Engl J Med 2003:348;2175 - 2185) . In Table 2 on page 2181, the percentage of patients in the enfuvirtide group with fewer than 400 copies of HIV-1 RNA per milliliter of plasma should have been 37.1, rather than 31.7, as printed.

Citing Articles (2)

Citing Articles

1. 1

   William Towner, Daniel Klein, Hai Linh Kerrigan, Stephen Follansbee, Kalvin Yu, Michael Horberg. (2009) Virologic Outcomes of Changing Enfuvirtide to Raltegravir in HIV-1 Patients Well Controlled on an Enfuvirtide Based Regimen: 24-Week Results of the CHEER Study. JAIDS Journal of Acquired Immune Deficiency Syndromes 51:4, 367-373
   CrossRef

2. 2

   Mark A Boyd. (2009) Improvements in antiretroviral therapy outcomes over calendar time. Current Opinion in HIV and AIDS 4:3, 194-199
   CrossRef